Summary of COVID-19 HH-120 studies

1. Song et al., Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 prevents SARS‐CoV‐2 infection: Two investigator‐initiated postexposure prophylaxis trials

186 patient HH-120 prophylaxis study: 76% fewer symptomatic cases (p=0.02) and 58% fewer cases (p=0.03).
RCT 269 participants showing significantly reduced risk of infection and symptomatic infection with IgM-like ACE2 fusion protein HH-120 nasal spray used as post-exposure prophylaxis. Participants self-administered HH-120 or placebo 5-10 times daily for up to 10 days. HH-120 reduced risk of infection by 64.6% in general contacts and 43.8% in close contacts, and reduced risk of symptomatic infection by 77.1% and 72.5%, respectively.
Dec 2023, J. Medical Virology, https://onlinelibrary.wiley.com/doi/10.1002/jmv.29275, https://c19p.org/song5

2. Song et al., Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study

168 patient HH-120 late treatment PSM study: 20% faster viral clearance (p=0.001).
PSM analysis of 65 HH-120 patients and 103 controls contemporaneously hospitalized in the same hospital, showing faster viral clearance with HH-120 treatment, with improved results for patients with higher baseline viral load.
May 2023, J. Medical Virology, https://onlinelibrary.wiley.com/doi/10.1002/jmv.28805, https://c19p.org/song6